896 related articles for article (PubMed ID: 25385004)
21. The rise and rise of stealth nanocarriers for cancer therapy: passive versus active targeting.
Huynh NT; Roger E; Lautram N; Benoît JP; Passirani C
Nanomedicine (Lond); 2010 Nov; 5(9):1415-33. PubMed ID: 21128723
[TBL] [Abstract][Full Text] [Related]
22. Current Advances in Chitosan Nanoparticles Based Oral Drug Delivery for Colorectal Cancer Treatment.
Choukaife H; Seyam S; Alallam B; Doolaanea AA; Alfatama M
Int J Nanomedicine; 2022; 17():3933-3966. PubMed ID: 36105620
[TBL] [Abstract][Full Text] [Related]
23. Tumor-targeting glycol chitosan nanocarriers: overcoming the challenges posed by chemotherapeutics.
Choi Y; Lim S; Yoon HY; Kim BS; Kwon IC; Kim K
Expert Opin Drug Deliv; 2019 Aug; 16(8):835-846. PubMed ID: 31343904
[No Abstract] [Full Text] [Related]
24. Demethoxycurcumin-carrying chitosan-antibody core-shell nanoparticles with multitherapeutic efficacy toward malignant A549 lung tumor: from in vitro characterization to in vivo evaluation.
Huang WT; Larsson M; Wang YJ; Chiou SH; Lin HY; Liu DM
Mol Pharm; 2015 Apr; 12(4):1242-9. PubMed ID: 25760774
[TBL] [Abstract][Full Text] [Related]
25. Transferrin-Conjugated Nanocarriers as Active-Targeted Drug Delivery Platforms for Cancer Therapy.
Nogueira-Librelotto DR; Codevilla CF; Farooqi A; Rolim CM
Curr Pharm Des; 2017; 23(3):454-466. PubMed ID: 27784246
[TBL] [Abstract][Full Text] [Related]
26. Nanocarriers-Mediated Drug Delivery Systems for Anticancer Agents: An Overview and Perspectives.
Edis Z; Wang J; Waqas MK; Ijaz M; Ijaz M
Int J Nanomedicine; 2021; 16():1313-1330. PubMed ID: 33628022
[TBL] [Abstract][Full Text] [Related]
27. pH-sensitive and specific ligand-conjugated chitosan nanogels for efficient drug delivery.
Xing L; Fan YT; Shen LJ; Yang CX; Liu XY; Ma YN; Qi LY; Cho KH; Cho CS; Jiang HL
Int J Biol Macromol; 2019 Dec; 141():85-97. PubMed ID: 31473314
[TBL] [Abstract][Full Text] [Related]
28. Polymeric nanoparticles for targeted drug delivery system for cancer therapy.
Masood F
Mater Sci Eng C Mater Biol Appl; 2016 Mar; 60():569-578. PubMed ID: 26706565
[TBL] [Abstract][Full Text] [Related]
29. Physicochemical, pharmaceutical and biological approaches toward designing optimized and efficient hydrophobically modified chitosan-based polymeric micelles as a nanocarrier system for targeted delivery of anticancer drugs.
Mahmoudzadeh M; Fassihi A; Emami J; Davies NM; Dorkoosh F
J Drug Target; 2013 Sep; 21(8):693-709. PubMed ID: 23915108
[TBL] [Abstract][Full Text] [Related]
30. An overview of active and passive targeting strategies to improve the nanocarriers efficiency to tumour sites.
Attia MF; Anton N; Wallyn J; Omran Z; Vandamme TF
J Pharm Pharmacol; 2019 Aug; 71(8):1185-1198. PubMed ID: 31049986
[TBL] [Abstract][Full Text] [Related]
31. Nanoparticles for tumor targeted therapies and their pharmacokinetics.
Wang J; Sui M; Fan W
Curr Drug Metab; 2010 Feb; 11(2):129-41. PubMed ID: 20359289
[TBL] [Abstract][Full Text] [Related]
32. The ligand nanoparticle conjugation approach for targeted cancer therapy.
Karra N; Benita S
Curr Drug Metab; 2012 Jan; 13(1):22-41. PubMed ID: 21892918
[TBL] [Abstract][Full Text] [Related]
33. Masking and triggered unmasking of targeting ligands on nanocarriers to improve drug delivery to brain tumors.
McNeeley KM; Karathanasis E; Annapragada AV; Bellamkonda RV
Biomaterials; 2009 Aug; 30(23-24):3986-95. PubMed ID: 19427688
[TBL] [Abstract][Full Text] [Related]
34. Tumor-targeting delivery of herb-based drugs with cell-penetrating/tumor-targeting peptide-modified nanocarriers.
Kebebe D; Liu Y; Wu Y; Vilakhamxay M; Liu Z; Li J
Int J Nanomedicine; 2018; 13():1425-1442. PubMed ID: 29563797
[TBL] [Abstract][Full Text] [Related]
35. Advances in using chitosan-based nanoparticles for in vitro and in vivo drug and gene delivery.
Duceppe N; Tabrizian M
Expert Opin Drug Deliv; 2010 Oct; 7(10):1191-207. PubMed ID: 20836623
[TBL] [Abstract][Full Text] [Related]
36. Role of pH-responsiveness in the design of chitosan-based cancer nanotherapeutics: A review.
Suarato G; Li W; Meng Y
Biointerphases; 2016 Dec; 11(4):04B201. PubMed ID: 27016506
[TBL] [Abstract][Full Text] [Related]
37. Chitosan Nanoparticles-Based Cancer Drug Delivery: Application and Challenges.
Sachdeva B; Sachdeva P; Negi A; Ghosh S; Han S; Dewanjee S; Jha SK; Bhaskar R; Sinha JK; Paiva-Santos AC; Jha NK; Kesari KK
Mar Drugs; 2023 Mar; 21(4):. PubMed ID: 37103352
[TBL] [Abstract][Full Text] [Related]
38. Dendronized Systems for the Delivery of Chemotherapeutics.
Dockery L; Daniel MC
Adv Cancer Res; 2018; 139():85-120. PubMed ID: 29941108
[TBL] [Abstract][Full Text] [Related]
39. Supramolecular Self-Assembled Nanogels a New Platform for Anticancer Drug Delivery.
Varshosaz J; Taymouri S; Ghassami E
Curr Pharm Des; 2017; 23(35):5242-5260. PubMed ID: 28699536
[TBL] [Abstract][Full Text] [Related]
40. Supramolecular nanoscale assemblies for cancer diagnosis and therapy.
Coelho SC; Pereira MC; Juzeniene A; Juzenas P; Coelho MAN
J Control Release; 2015 Sep; 213():152-167. PubMed ID: 26160308
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
